JP2009534373A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009534373A5 JP2009534373A5 JP2009506041A JP2009506041A JP2009534373A5 JP 2009534373 A5 JP2009534373 A5 JP 2009534373A5 JP 2009506041 A JP2009506041 A JP 2009506041A JP 2009506041 A JP2009506041 A JP 2009506041A JP 2009534373 A5 JP2009534373 A5 JP 2009534373A5
- Authority
- JP
- Japan
- Prior art keywords
- hydroxymethyl
- cis
- amino
- pharmaceutical composition
- pyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013078 crystal Substances 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims 5
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 239000003960 organic solvent Substances 0.000 claims 3
- 238000003756 stirring Methods 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- -1 aliphatic alcohols Chemical class 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 238000001816 cooling Methods 0.000 claims 2
- 238000001035 drying Methods 0.000 claims 2
- 238000010438 heat treatment Methods 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 229960001627 lamivudine Drugs 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 238000000113 differential scanning calorimetry Methods 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000012452 mother liquor Substances 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 claims 1
- 238000000646 scanning calorimetry Methods 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 238000002411 thermogravimetry Methods 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN347/KOL/2006 | 2006-04-18 | ||
| IN347KO2006 | 2006-04-18 | ||
| PCT/IN2007/000047 WO2007119248A1 (en) | 2006-04-18 | 2007-02-09 | A novel crystalline form of lamivudine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009534373A JP2009534373A (ja) | 2009-09-24 |
| JP2009534373A5 true JP2009534373A5 (enExample) | 2010-04-02 |
| JP5184511B2 JP5184511B2 (ja) | 2013-04-17 |
Family
ID=37969898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009506041A Expired - Fee Related JP5184511B2 (ja) | 2006-04-18 | 2007-02-09 | 新しい結晶形態のラミブジン |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8158607B2 (enExample) |
| EP (1) | EP2007758B1 (enExample) |
| JP (1) | JP5184511B2 (enExample) |
| AT (1) | ATE485292T1 (enExample) |
| AU (1) | AU2007237818B2 (enExample) |
| CA (1) | CA2649796A1 (enExample) |
| DE (1) | DE602007009957D1 (enExample) |
| ES (1) | ES2357159T3 (enExample) |
| WO (1) | WO2007119248A1 (enExample) |
| ZA (1) | ZA200809820B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100190982A1 (en) * | 2007-09-17 | 2010-07-29 | Janardhana Rao Vascuri | Process for the preparation of lamivudine form i |
| AU2008331168A1 (en) * | 2007-11-29 | 2009-06-04 | Ranbaxy Laboratories Limited | Crystalline form I of lamivudine and its preparation |
| WO2009069014A1 (en) * | 2007-11-29 | 2009-06-04 | Ranbaxy Laboratories Limited | Amorphous lamivudine and its preparation |
| WO2009116055A1 (en) * | 2008-03-17 | 2009-09-24 | Lupin Limited | Lamivudine : zidovudine : water 1 : 1 : 1 cocrystal |
| WO2009127996A1 (en) * | 2008-04-17 | 2009-10-22 | Ranbaxy Laboratories Limited | Novel crystalline form of lamivudine |
| EP2318398A4 (en) | 2008-09-01 | 2011-12-07 | Hetero Research Foundation | PROCESS FOR PREPARING A POLYMORPHIC FORM OF LAMIVUDIN |
| US8481554B2 (en) | 2009-05-27 | 2013-07-09 | Hetero Research Foundation | Solid oral dosage forms of lamivudine |
| EP2488516B1 (en) | 2009-10-14 | 2015-04-01 | Mylan Laboratories Limited | Process for the preparation of lamivudine and novel salts in the manufacture thereof |
| WO2011100381A1 (en) * | 2010-02-12 | 2011-08-18 | Merck Sharp & Dohme Corp. | Preparation of lamivudine form i |
| WO2013168066A1 (en) | 2012-05-05 | 2013-11-14 | Lupin Limited | An improved process for the manufacture of lamivudine form i. |
| CA2898092A1 (en) * | 2013-02-07 | 2014-08-14 | Tobira Therapeutics, Inc. | Lamivudine salts |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5047407A (en) * | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
| US5204466A (en) * | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
| GB9009861D0 (en) | 1990-05-02 | 1990-06-27 | Glaxo Group Ltd | Chemical compounds |
| GB9111902D0 (en) * | 1991-06-03 | 1991-07-24 | Glaxo Group Ltd | Chemical compounds |
| WO2003027106A1 (en) * | 2001-09-25 | 2003-04-03 | Cadila Healthcar Limited | Process for the preparation of crystalline polymorph ii of lamivudine |
-
2007
- 2007-02-09 AU AU2007237818A patent/AU2007237818B2/en not_active Ceased
- 2007-02-09 AT AT07706193T patent/ATE485292T1/de not_active IP Right Cessation
- 2007-02-09 DE DE602007009957T patent/DE602007009957D1/de active Active
- 2007-02-09 US US12/297,174 patent/US8158607B2/en not_active Expired - Fee Related
- 2007-02-09 CA CA002649796A patent/CA2649796A1/en not_active Abandoned
- 2007-02-09 EP EP07706193A patent/EP2007758B1/en not_active Not-in-force
- 2007-02-09 ES ES07706193T patent/ES2357159T3/es active Active
- 2007-02-09 WO PCT/IN2007/000047 patent/WO2007119248A1/en not_active Ceased
- 2007-02-09 JP JP2009506041A patent/JP5184511B2/ja not_active Expired - Fee Related
-
2008
- 2008-11-18 ZA ZA2008/09820A patent/ZA200809820B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009534373A5 (enExample) | ||
| CN101573368B (zh) | 结晶型1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯半水合物 | |
| JP7241916B2 (ja) | ７ｈ－ピロロ［２，３－ｄ］ピリミジンｊａｋ－阻害剤 | |
| EP2007758B1 (en) | A novel crystalline form of lamivudine | |
| ES2351958T3 (es) | 5-cloro-3-(4-metanosulfonilfenil)-6'-metil-[2,3'] bipiridinil en forma cristalina pura y procedimiento de síntesis. | |
| HRP20120007T1 (hr) | Polimorfni oblik 4-[3-(4-ciklopropankarbonil-piperazin-1-karbonil)-4-fluoro-benzil]-2h-ftalazin-1-ona | |
| JP2008513358A5 (enExample) | ||
| JP2020536893A5 (enExample) | ||
| BRPI0615383A2 (pt) | formas de cristal delta e épsilon de mesilato de imatinib | |
| TW201213325A (en) | Crystalline forms of pyrimidio [6,1-A] isoquinolin-4-one compounds | |
| TW200845998A (en) | Heterocyclic compounds useful in treating diseases and conditions | |
| JP2016503010A5 (enExample) | ||
| TW202200594A (zh) | 一種glp-1受體激動劑的晶型a及其製備方法 | |
| JP2010514725A5 (enExample) | ||
| JP2005529084A5 (enExample) | ||
| US10947225B2 (en) | Phosphotidylinositol 3-kinase inhibitors | |
| JP2010540470A5 (enExample) | ||
| JP2013541589A5 (enExample) | ||
| TWI815820B (zh) | ２－（５－（４－（２－嗎啉乙氧基）苯基）吡啶－２－基）－ｎ－芐乙醯胺之固態形式 | |
| TW201412732A (zh) | 二氫嘧啶衍生物的晶型 | |
| JP2010540440A5 (enExample) | ||
| CN101993417A (zh) | 磷酸二甲啡烷的稳定新晶型 | |
| CN115536654A (zh) | 小檗碱橙皮素盐晶型及其制备方法和其组合物与应用 | |
| CN104230758B (zh) | 盐酸珍米洛非班的晶型 | |
| CN104926839B (zh) | 具有生物活性的四氢咪唑并噻唑并吡啶盐酸盐类化合物及其制备方法 |